Cargando…
Molecular signaling in multiple myeloma: association of RAS/RAF mutations and MEK/ERK pathway activation
Multiple myeloma (MM) is a plasma cell malignancy that is still considered to be incurable in most cases. A dominant mutation cluster has been identified in RAS/RAF genes, emphasizing the potential significance of RAS/RAF/MEK/ERK signaling as a therapeutic target. As yet, however, the clinical relev...
Autores principales: | Xu, J, Pfarr, N, Endris, V, Mai, E K, Md Hanafiah, N H, Lehners, N, Penzel, R, Weichert, W, Ho, A D, Schirmacher, P, Goldschmidt, H, Andrulis, M, Raab, M S |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5523069/ https://www.ncbi.nlm.nih.gov/pubmed/28504689 http://dx.doi.org/10.1038/oncsis.2017.36 |
Ejemplares similares
-
Polymorphisms in RAS/RAF/MEK/ERK Pathway Are Associated with Gastric Cancer
por: Gonzalez-Hormazabal, Patricio, et al.
Publicado: (2018) -
Targeting Aberrant RAS/RAF/MEK/ERK Signaling for Cancer Therapy
por: Degirmenci, Ufuk, et al.
Publicado: (2020) -
Reusability and composability in process description maps: RAS–RAF–MEK–ERK signalling
por: Mazein, Alexander, et al.
Publicado: (2021) -
A personalized molecular approach in multiple myeloma: the possible use of RAF/RAS/MEK/ERK and BCL-2 inhibitors
por: Raimondi, Vincenzo, et al.
Publicado: (2022) -
Modulation of the Akt/Ras/Raf/MEK/ERK pathway by A(3) adenosine receptor
por: Merighi, Stefania, et al.
Publicado: (2006)